Aggregation-prone motifs in human immunoglobulin G
- PMID: 19527731
- DOI: 10.1016/j.jmb.2009.06.028
Aggregation-prone motifs in human immunoglobulin G
Abstract
Therapeutic antibodies of many different IgG subclasses (IgG1, IgG2 and IgG4) are used in the treatment of various cancers, rheumatoid arthritis and other inflammatory and infectious diseases. These antibodies are stored for long durations under high concentrations as required in the disease treatment. Unfortunately, these antibodies aggregate under these storage conditions, leading to a decrease in antibody activity and raising concerns about causing an immunological response. Thus, there is a tremendous need to identify the aggregation-prone regions in different classes of antibodies. We use the SAP (spatial-aggregation-propensity) technology based on molecular simulations to determine the aggregation-prone motifs in the constant regions of IgG1 classes of antibodies. Mutations engineered on these aggregation-prone motif regions led to antibodies of enhanced stability. Fourteen aggregation-prone motifs are identified, with each motif containing one to seven residues. While some of these motifs contain residues that are neighbors in primary sequence, others contain residues that are far apart in primary sequence but are close together in the tertiary structure. Comparison of the IgG1 sequence with those of other subclasses (IgG2, IgG3 and IgG4) showed that these aggregation-prone motifs are largely preserved among all IgG subclasses. Other broader classes of antibodies (IgA1, IgD, IgE and IgM), however, differed in these motif regions. The aggregation-prone motifs identified were therefore common to all IgG subclasses, but differ from those of non-IgG classes. Moreover, since the motifs identified are in the constant regions, they are applicable for all antibodies within the IgG class irrespective of the variable region. Thus, the motif regions identified could be modified on all IgGs to yield antibodies of enhanced stability.
Similar articles
-
Prediction of aggregation prone regions of therapeutic proteins.J Phys Chem B. 2010 May 20;114(19):6614-24. doi: 10.1021/jp911706q. J Phys Chem B. 2010. PMID: 20411962
-
Antibody therapeutics, antibody engineering, and the merits of protein stability.Curr Opin Drug Discov Devel. 2008 Sep;11(5):675-87. Curr Opin Drug Discov Devel. 2008. PMID: 18729019 Review.
-
Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum.Proteomics. 2007 Nov;7(22):4070-81. doi: 10.1002/pmic.200700289. Proteomics. 2007. PMID: 17994628
-
Flexibility of human IgG subclasses.J Immunol. 1997 Oct 1;159(7):3372-82. J Immunol. 1997. PMID: 9317136
-
IgG subclasses of human autoantibodies.Ann Med Interne (Paris). 1997;148(1):29-38. Ann Med Interne (Paris). 1997. PMID: 9137697 Review.
Cited by
-
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins.MAbs. 2023 Jan-Dec;15(1):2220150. doi: 10.1080/19420862.2023.2220150. MAbs. 2023. PMID: 37278452 Free PMC article. Review.
-
Non-specificity as the sticky problem in therapeutic antibody development.Nat Rev Chem. 2022 Dec;6(12):844-861. doi: 10.1038/s41570-022-00438-x. Epub 2022 Nov 14. Nat Rev Chem. 2022. PMID: 37117703 Review.
-
Multidimensional Protein Solubility Optimization with an Ultrahigh-Throughput Microfluidic Platform.Anal Chem. 2023 Mar 28;95(12):5362-5368. doi: 10.1021/acs.analchem.2c05495. Epub 2023 Mar 17. Anal Chem. 2023. PMID: 36930285 Free PMC article.
-
Recombinant antibodies aggregation and overcoming strategies in CHO cells.Appl Microbiol Biotechnol. 2022 Jun;106(11):3913-3922. doi: 10.1007/s00253-022-11977-0. Epub 2022 May 24. Appl Microbiol Biotechnol. 2022. PMID: 35608667 Review.
-
Two physics-based models for pH-dependent calculations of protein solubility.Protein Sci. 2022 May;31(5):e4299. doi: 10.1002/pro.4299. Protein Sci. 2022. PMID: 35481654 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous